SAB Biotherapeutics (SABS) Gains from Investment Securities (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Gains from Investment Securities came in at $482474.0 in Q1 2026, up 109.58% YoY from $230208.9 in Q1 2025, and down 85.17% on a QoQ basis from $3.3 million in Q4 2025.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Gains from Investment Securities (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Gains from Investment Securities data on file, last reported at $482474.0 in Q1 2026.
- Quarterly Gains from Investment Securities rose 109.58% year-over-year to $482474.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.2 million (down 1055.68% YoY) and the FY2025 annual result came in at -$62.8 million, down 1065.35% from the prior year.
- Gains from Investment Securities fell to $482474.0 in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $4.7 million in Q4 2023 to a low of -$61.6 million in Q3 2025.
- A 5-year average of -$4.3 million and a median of -$82586.0 in 2023 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 13020.42% — and 2025, when it sank 998099.77%.
- Tracing SABS's Gains from Investment Securities over 5 years: stood at -$36586.0 in 2022, then surged by 13020.42% to $4.7 million in 2023, then sank by 51.21% to $2.3 million in 2024, then jumped by 41.06% to $3.3 million in 2025, then plunged by 85.17% to $482474.0 in 2026.
- The last three Gains from Investment Securities figures came in at $482474.0 (Q1 2026), $3.3 million (Q4 2025), and -$61.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Mar 31, 2026 | 482,474.00 |
| Dec 31, 2025 | 3.25 Mn |
| Sep 30, 2025 | -61.60 Mn |
| Jun 30, 2025 | 627,000.00 |
| Mar 31, 2025 | -5.04 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Sep 30, 2024 | -6,171.00 |
| Jun 30, 2024 | -2.22 Mn |
| Mar 31, 2024 | -5.47 Mn |
| Dec 31, 2023 | 4.73 Mn |
| Sep 30, 2023 | -178,758.00 |
| Jun 30, 2023 | 357,516.00 |
| Mar 31, 2023 | -82,586.00 |
| Dec 31, 2022 | -36,586.00 |
| Sep 30, 2022 | -782,962.00 |
| Jun 30, 2022 | -1.73 Mn |
| Mar 31, 2022 | -7.85 Mn |
| Dec 31, 2021 | 5.65 Mn |
| Sep 30, 2021 | -1,794.00 |